HER-2靶向的抗体与细胞免疫疗法研究进展  

Research progress of HER-2 targeted antibody and cellular immunotherapy

作　　者：郑航 郑源强[1] 石艳春[1] 陈国江 Zheng Hang;Zheng Yuanqiang;Shi Yanchun;Chen Guojiang(Inner Mongolia Key Laboratory of Molecular Biology,Inner Mongolia Medical University,Hohhot 010058,China;State Key Laboratory of Antitoxic Drugs and Toxicology,Academy of Military Medicine,Academy of Military Sciences,Beijing 100850,China)

机构地区：[1]内蒙古医科大学内蒙古自治区分子生物学重点实验室,呼和浩特010058 [2]军事科学院军事医学研究院抗毒药物与毒理学国家重点实验室,北京100850

出　　处：《国际免疫学杂志》2023年第2期163-168,共6页International Journal of Immunology

基　　金：国家自然科学基金(81672803,81871252)。

摘　　要：人类表皮生长因子受体2(human epidermal growth factor receptor-2,HER-2)是一种跨膜糖蛋白,属于表皮生长因子受体(epidermal growth factor receptor,EGFR)家族。该蛋白包括三个区域:细胞外配体结合区、单次跨膜区和负责信号转导的细胞内细胞质酪氨酸激酶区。HER-2在乳腺癌、胃癌、食管癌、头颈部肿瘤和妇科肿瘤等多种实体肿瘤中高表达,可以作为抗肿瘤药物的靶点。目前针对HER-2蛋白的药物(单克隆抗体、双抗、抗体偶联药物等)均显示出良好的效果。文章主要综述了靶向HER-2药物的最新进展。Human epidermal growth factor receptor-2(HER-2)is a transmembrane glycoprotein belonging to the epidermal growth factor receptor(EGFR)family.The protein consists of three regions:extracellular ligand binding region,single transmembrane region and intracellular tyrosine kinase region responsible for signal transduction.HER-2 is highly expressed in breast cancer,gastric cancer,esophageal cancer,head and neck tumors,gynecological tumors and other solid tumors,and can be used as a target for antineoplastic drugs.At present,the drugs aimed at HER-2 protein(monoclonal antibody,double antibody,antibody-drug conjugates,etc.)have shown good results.This review focuses on the latest development of drugs targeting HER-2.

关 键 词：人类表皮生长因子受体2 单克隆抗体 双特异性抗体 抗体偶联药物 细胞过继免疫治疗 

分 类 号：R730.51[医药卫生—肿瘤]